Chugai Calls Attention To Teratogenicity Related To Keratosis Drug Tegison In Japan
This article was originally published in PharmAsia News
Executive Summary
After receiving a report that another baby with congenital abnormalities was born in November 2013 to a mother who had used Tegison (etretinate) for keratosis treatment, Chugai once again warned health care workers that the drug must not be prescribed to women who are pregnant or possibly pregnant.